Mark N. Stein, MD

Dr. Cindy Elizabeth Neunert is a board-certified specialist in Pediatric Hematology and Oncology, providing expert care for children with various blood disorders and cancers. She is affiliated with New York Presbyterian and Columbia University Irving Medical Center, where she also serves as an Assistant Professor of Pediatrics. Her clinical expertise includes the treatment of anemia, bleeding and clotting disorders, pediatric hemophilia, leukemia, vascular anomalies, and sickle cell anemia. Dr. Neunert completed her fellowship at the University of Texas Southwestern Medical Center and her residency at Eastern Virginia Medical Center, ensuring a comprehensive approach to pediatric care. Generated from the website

Dr. Ryan Moy is an Assistant Professor of Medicine and medical oncologist at Columbia University Irving Medical Center where he specializes in the treatment of gastrointestinal malignancies, with a focus on esophageal and stomach cancers. He received his MD/PhD from the University of Pennsylvania and completed internship and residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He then completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center and postdoctoral research at The Rockefeller University. Dr. Moy is actively involved in translational research to understand the biological mechanisms that regulate metastasis, the primary driver of mortality in gastrointestinal cancers. He has performed laboratory-based research to define critical genes that promote liver metastasis in colorectal cancer. He is also conducting research to discover key vulnerabilities in esophageal and gastric cancers, with the goal of translating these findings from the lab to develop more effective treatments for patients. As an active member of the gastrointestinal oncology and experimental therapeutics groups, Dr. Moy is involved in developing and leading clinical trials investigating novel targeted and immunotherapy treatments for esophagogastric cancer and other malignancies. His work has been recognized by several awards including a Damon Runyon Cancer Research Foundation Fellow Award and a National Cancer Institute (NCI) K08 Career Development Award. Dr. Moy works as part of a multidisciplinary team with the mission of delivering compassionate and state-of-the-art oncologic care to each patient, using a precision medicine approach to provide innovative and promising treatments.

Dr. Hua-Jay “Jeff” Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. He has participated in the Academy of Next Wave of Investigators for non-Hodgkin’s lymphoma and the American Society of Hematology Clinical Research Training Institute. His research on ctDNA has been funded by a Conquer Cancer Young Investigator Award and Career Development Award as well as a NIH/NCI R03 Small Research Grant. He is a member of the SWOG Lymphoma Working Group and Committee. Dr. Cherng’s designs clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.